Chapter-1 Page 3 that increase the possibility of developing Alzheimer's. Numerous endogenous and exogenous Alzheimer's disease risk factors have been recognized, herein termed Alzheimer's risk factors (ARF). Various factors undoubtedly work synergistically and additively to increase Alzheimer's disease risk.
Risk factors are two types;
Non-modifiable risk factors and modifiable risk factors.
Non-modifiable Alzheimer's risk factors (i) Age
Aging is a greatest known risk factor for Alzheimer's disease. Most of the persons with the Alzheimer's are 65 and older. The probability of developing Alzheimer's approximately two times every five years after age 65. After age 85, the risk attains nearly 50%. An entropic (increasing disorder) analysis of Alzheimer's disease, precisely pointing to advancing age as the most significant risk factor for the disease and hypothesizing aging alone could account for its causation [4] . Argument of Drachman against seeking a single pathophysiological factor (e.g., amyloid accumulation), but rather suggested effective Alzheimer's disease prevention might instead depend on recognition of contributions from a multiplicity of age related changes and reducing their burden as much as possible.
(ii) Family history and genetic susceptibility
Research has revealed that those who have a parent, brother or sister with Alzheimer's are two to three times more probable to develop the disease. The risk increases if more than one family member has the Alzheimer's disease. Although late-onset Alzheimer's disease, the most common form of the disease, has relatively minor heritability [5] .
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(iii) Down syndrome
Down syndrome is firmly established as extremely genetic and major risk factor for AD. Down syndrome is a developmental disorder caused by inheritance of an additional copy of chromosome 21, although the etiological relationship between the chromosome 21 genes and the Down syndrome pheno-type is multifaceted [6] . A gene that encodes for amyloid precursor protein (APP) resides on chromosome 21. It is thought on Down syndrome the extra copy of the amyloid precursor protein gene once activated can cause abnormalities in the processing of amyloid and its subsequent deposition in plaque. Other than in Down syndrome, inherited alteration of this gene causes an autosomal dominant form of Alzheimer's disease [7] .
(iv) Traumatic brain injury (TBI)
All major head injuries, including concussions, can considerably increase the risk of Alzheimer's disease. Within a few hours following TBI, abnormal patterns of amyloid and tau deposition appear in injured brain tissue [8] . Frequent mild Traumatic brain injury accelerates amyloid deposition and rates cognitive impairment. Sports such as boxing, ice hockey, soccer and football facilitate head injuries. Boxers who have had 10 or more brain injuries and who have the ApoE4 gene tend to have worse cognitive outcomes than those lacking the gene [9] .
Modifiable Alzheimer's risk factors (i) Obesity
Obesity is a proven risk factor for Alzheimer's disease. A study that tracked 1500 people for 18 years concluded midlife obesity more than doubles the risk for Alzheimer's disease [10] .
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(ii) Type 2 diabetes Type 2 diabetes is connected to higher Alzheimer's risk. In diabetes, hyperinusulinemia almost doubles the risk for Alzheimer's disease compared to people without diabetes [11] . There is also good evidence of hyperinusulinemia accelerates functional cognitive decline [12] . Furthermore, insulin resistance is implicated in the pathogenesis of AD [13] .
(iii) Homocysteine
An elevated blood level of homocysteine, a metabolic of methionine, is a risk factor for Alzheimer's disease [14] . Comprehensively research studies connected homocysteine to increase Alzheimer's risk [15] . Documenting many studies indicating vitamins B6, B12
and folate can effectively lower homocysteine.
(iv) Cardiovascular abnormalities
Poor brain circulation has been more closely linked to vascular dementia than to AD, many cases of an AD are complicated by the presence of micro-lesions denoting blood vessel breakages mini strokes [16] .
(v) Hypertension
Hypertension at midlife is linked to significantly increase the risk for AD [17] .
Signs and symptoms
The patient normally visits the physician at the behest of his family. The family typically detects an example of changing behaviors that can include following signs and symptoms Alzheimer's disease has been classified into three stages.
 Stage one generally lasts two to four years. It involves forgetfulness, confusion, disorientation, mood changes and recent memory loss.
 Stage two frequently lasts two to ten years. It characteristically is characterized by decreased memory functioning, reduced attention span, hallucinations, wandering, restlessness, muscle spasms, reduced ability to perform logic, increased irritability, and an increased inability to organize thoughts.
 Stage three generally lasts one to three years. This stage most often involves the increased incapability to identify family members, a progressive incapacity to recognize their own image in the mirror, incontinence, weight loss, swallowing difficulty and development of skin infections.
Diagnosis
The most extensively accepted diagnostic criteria for likely Alzheimer's disease (AD) were developed by the U.S. National institute of neurological and communicative disorder and stroke (NINDS), AD and related disorders association joint working group.
The diagnosis of AD is based on the presence of confirmed memory impairment and the Chapter-1 Page 7 presence of single or additional of the following three cognitive deficits: Alzheimer's disease. The recent study showed that acetylcholinesterase (AChE) plays role in accelerating αβ plaques deposition. Thus, the cholinergic hypothesis has become the leading strategy for the development of anti-Alzheimer's disease agents which are inhibitors of acetylcholinesterase (AChE) [20] .
Current research therapeutic strategies for Alzheimer's disease treatment.
The treatment of Alzheimer's disease has progressed and shifted since the late 1970s to a transmitter replacement strategy. There has been no cure so far to stop Alzheimer's disease, while only symptomatic treatment is available. The pathology of Alzheimer's disease consists of a combination of genetic and non-genetic multi-factors. Between them, one theory named as "the cholinergic hypothesis" has been suggested leading to a discovery of "acetylcholinesterase (AChE) inhibitors". The most effective treatments are Chapter-1 Page 10 the medications that attempt to increase the brain's levels of acetylcholine, an important neurotransmitter whose levels decrease with the onset of the disease. Elevation of acetylcholine levels in the brain through the use of AChE inhibitors has been accepted as the most effective treatment strategy against AD [21] .
Cholinesterase is a family of enzymes that catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation.
Cholinesterase has two types  Acetylcholinesterase (AChE) also known as acetylcholine acetylhydrolase.
 Butylcholinesterase (BuChE) also known as plasma cholinesterase, acylcholine acylhydrolase, butyrylcholinesterase.
Therefore, Acetylcholinesterase (AChE) and butyl cholinesterase (BuChE) inhibitors have become the drug of choice in the management of Alzheimer's disease [22] . Several acetylcholinesterase AChE inhibitors named as cognitive enhancers are being investigated for the symptomatic treatment of Alzheimer's disease. In our research, we aim to put focus particularly on the Acetylcholinesterase inhibitors compounds used in the treatment of Alzheimer's disease.
A role of acetylcholine and acetylcholinesterase for the Alzheimer's disease.

Acetylcholine
The chemical compound acetylcholine (often abbreviated ACh) is a neurotransmitter in both the peripheral nervous system (PNS) and central nervous system (CNS) in many organisms including humans. In the peripheral nervous system, acetylcholine (ACh) is the neurotransmitter at the neuromuscular junction between the motor nerve and skeletal Chapter-1 Page 11 muscle. In the central nervous system, acetylcholine is found primarily in interneurons, and a few important long-axon cholinergic pathways have also been identified.
Nerve cells in the brain communicate to each other by releasing chemicals, these chemicals are called neurotransmitters. Acetylcholine is significant neurotransmitters for memory. Peoples with Alzheimer's disease contain low levels of acetylcholine in their brain. It is chiefly found at neuromuscular junctions and cholinergic system, where its activity serves to terminate synaptic transmission. Acetylcholine slows the heart rate when functioning as an inhibitory neurotransmitter. Though, acetylcholine also performs as an excitatory neurotransmitter at neuromuscular junctions [23] . The mechanism involved in cholinesterase inhibitor drugs involves the blocking breakdown of ACh, therefore elevating ACh levels at the cholinergic synapses and reimbursing for loss of cholinergic circuits [24] . fig. 1.2.1. and fig. 1 
Acetylcholinesterase (AChE)
Acetylcholinesterase also was known as AChE or acetylcholine acetylhydrolase is an enzyme that degrades (through its hydrolytic activity) acetylcholine in the brain .if their action is inhibited, more acetylcholine is available for communication between the nerve cells. Acetylcholinesterase is a serine hydrolase mainly found at neuromuscular junctions and cholinergic brain synapses. Its significant biological role is termination of impulse transmission at cholinergic synapses by rapid hydrolysis of the neurotransmitter ACh to acetate and choline. Acetylcholinesterase has an extremely high catalytic activity each molecule of AChE degrades about 25000 molecules of acetylcholine per second. The choline produced by the action of AChE is recycled, transported, through reuptake, back into nerve terminals where it is used to synthesize new acetylcholine molecules [25] .
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A brief review of drugs treatments for the AD as acetylcholinesterase inhibitors.
There is a considerable amount of medical research that is currently taking place to discover efficient therapeutic treatments for Alzheimer's disease. Acetylcholinesterase inhibitor drugs stop or slow down enzymes from breaking down acetylcholine when it passes from one cell to another. This signifies that the acetylcholine, which is, in short, delivery in people with AD is not damaged so rapidly and there is extra chance of it being passed on to the next nerve cell. Regions of the brain that depend principally on cholinergic circuitry are normally the first and most harshly damaged by Alzheimer's disease [26] . Side effects: Gastrointestinal anomalies, bradycardia, abdominal pain nausea, diarrhea and anorexia [28, 29] .
Chapter-1
Page 15
Tacrine Fig.1.3.2 . Structure of Tacrine.
Tacrine is a centrally acting anticholinesterase inhibitor and indirect cholinergic agonist.
The drug that acts to increase the concentration of acetylcholine in the brain. It was the first centrally acting prototypical cholinesterase inhibitor approved for the treatment of Alzheimer's disease in 1993. Its immediate successor, approved for all stages of Alzheimer's disease. Recent studies found that patients taking tacrine need to have liver monitoring on a weekly basis because of its potential to damage the liver. It also acts as a histamine N-methyltransferase inhibitor [30] .
Side effects: Nausea, vomiting, salivation, sweating, bradycardia, hypotension, collapse, convulsions and liver toxicity [31, 32] .
Rivastigmine Fig.1.3.3 . Structure of Rivastigmine.
Rivastigmine is an acetylcholinesterase inhibitor; it is the consideration to work by inhibiting cholinesterase enzymes which would otherwise break down the brain neurotransmitter acetylcholine [33] . It is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's. The drug is administered orally as capsules or liquid formulations, with good absorption and bioavailability of Chapter-1 Page 16 about 40% in the 3 mg dose. It is eliminated through the urine and has relatively few drug-drug interactions. Early and continued treatment of AD with rivastigmine maximizes the observed beneficial effects in the rate of decline of cognitive function, activities of daily living and severity of dementia with daily doses of 6 to 12 mg.
Side effects: Bradycardia, nausea, diarrhea, and anorexia [34, 35] .
Galantamine Fig.1.3.4 . Structure of Galanthamine.
Galantamine used as a cholinergic enhancer in the treatment of Alzheimer's disease. It is an isoquinoline alkaloid that has been isolated from the bulbs and flowers of Galanthus woronowii (Amaryllidaceae) known as "snowdrop" [36] .
Galantamine completely inhibits acetylcholinesterase (AChE) enzyme which hydrolyzes acetylcholine. As a result of acetylcholinesterase (AChE) inhibition increases the availability of acetylcholine for synaptic transmission [37] .
Side effects: Bradycardia and nausea.
Alternative approaches to Alzheimer's disease prevention
There is rising evidence that lifestyle, including a diet rich in antioxidant, neuroprotective and anti-inflammatory agents might diminish the risk of developing Alzheimer's disease.
The Mediterranean diet, known for first and foremost as a way to protect against heart disease, may decrease the incidence of Alzheimer's disease. This diet, along with others, may help prevent the development of Alzheimer's disease by possibly scavenging Chapter-1 Page 17 reactive oxygen species, intensification the ability of neurons to protect themselves. The alternative therapies to Prevent Alzheimer's disease were follows.
Diet Therapy
There is accumulating evidence that diet is important in the prevention and control of Alzheimer's disease. One of the main concerns in an Alzheimer's patient is to maintain sufficient nutrient intake and prevent malnourishment. Research indicates a diet high in carbohydrates is more appealing to the Alzheimer's patient and will lead to improved levels of food intake. The Mediterranean diet that involves the high intake of monounsaturated fats, wine and cereals has been connected with an increased risk of cognitive decline.
Nutritional Therapy
Vitamin E
Vitamin E is a renowned antioxidant that is a good candidate to stop or halt the progression of the characteristic biological processes linked with Alzheimer's disease.
Newer evidence in animal studies has further confirmed the importance of vitamin E deficiency in the development of Alzheimer's disease [38] . An epidemiological study has found that vitamin E has strong effects against oxidative processes in the brain and that the collective use of vitamin E and vitamin C reduced the occurrence of developing Alzheimer's disease by 64% over a lifetime [39] .
Vitamin B12
A newer study found that vitamin B12 deficiency in patients who already have AD is more likely to have a diversity of neuropsychological disorders than those with more normal levels of vitamin B12 in the blood [40] . A study found that vitamin B12 levels are Chapter-1 Page 18 significant in the prevention of Alzheimer's disease, but the researchers found that once Alzheimer's disease develops, vitamin B12 supplementation is of little benefit in the control of the disease [41] .
Folic acid
Folic acid is known to play a very important role in a variety of biological processes in the body. Folic acid deficiencies have been linked with the development of depression. A study of depressed patients found that 31-35 percent of the individuals were folic aciddeficient [42] . This type of depression is more common in the elderly. The correction of folic acid deficiencies in these elderly patients often results in the correction of depression [43] . Depression is also one of the most common presenting symptoms of Alzheimer's disease.
Dehydroepiandrosterone (DHEA)
Dehydroepiandrosterone is the most common hormone in the body. It also found in large quantities in the brain. A case-control study found that a group of 14 persons with Alzheimer's disease had considerably lower levels of DHEA sulfate in the plasma compared to13 matched healthy controls [44] . A new study of patients with Alzheimer's disease found that the administration of DHEA sulfate combined with insulin improved a variety of physiologic factors associated with the Alzheimer's disease [45] .
Zinc
Zinc deficiency has been quoted as a factor in the development of Alzheimer's disease [46] . Zinc is involved in a wide variety of cellular processes, particularly in the formation of enzymes critical to the replication of DNA and in the creation of proteins. Zinc is also a significant factor in antioxidation processes. It is generally accepted by scientists that Chapter-1 Page 19 Alzheimer's disease caused by oxidation processes. Insufficient quantities of zinc in the body could be associated with the destruction of nerve cells and the formation of plaques and tangles that is associated with Alzheimer's. A study of 10 Alzheimer's patients who were given 27 milligrams of zinc daily found that 8 patients had specific improvement in social behavior, comprehension ability, and communication skills, memory performance [47] . Additional research is needed to determine the suitable dietary levels of zinc to prevent Alzheimer's disease.
Phosphatidylcholine
Researchers have found that phosphatidylcholine a key substance found in lecithin, supplementation can lead to increased levels of acetylcholine in the brain. This would propose that phosphatidylcholine would be effective in treating Alzheimer's disease. A new study has provided evidence that phosphatidylcholine breaks down at a faster rate in Alzheimer's disease patients than in healthy persons [48] . This proposes a role for phosphatidylcholine supplementation in Alzheimer's patients. A new study found that a combination of vitamin E, pyruvate, and phosphatidylcholine provides more protection against brain oxidation processes in dementia-type diseases than vitamin E alone [49] .
Antioxidants
Alzheimer's disease is a process characterized by oxidative properties. Therefore, antioxidants, in general, should have positive effects in both the prevention and treatment of Alzheimer's. A study found that antioxidants such as vitamin A, vitamin D, lycopene, and beta-carotene were all significantly lower in Alzheimer's disease patients than controls [50] . The most excellent studied of the remaining antioxidants is vitamin C. A case study found that plasma vitamin C levels are lower in patients with Alzheimer's Chapter-1 Page 20 disease and that these levels are associated with the degree of cognitive impairment [51] .
A prospective study of 633 patients aged 65 years and older found that high-dose supplementation with vitamin C reduced the risk of developing Alzheimer's disease [52] .
Music Therapy
Numerous studies have demonstrated that music therapy provides positive effects to Alzheimer's patients. A study of 18 elderly Alzheimer's patients aged 55-95 years with severe disease found that music played during bath time led to significant decreases in aggressive behavior events over a two-week period [53] . A study found that music therapy produces a variety of behavioral, stress, and immunological effects that are associated with positive memory changes in Alzheimer's disease patients [54] .
Therapeutic Touch and Massage therapy
The researchers found that the therapeutic touch therapy significantly reduced discomfort in Alzheimer's patients. A study that measured anxiety and dysfunctional behavior in Alzheimer patients found that expressive physical touch combined with visualization led to decreased anxiety and dysfunctional behavior in advanced Alzheimer patients [55] . A different study found that both therapeutic touch and hand massage reduced agitation levels in these patients [56] .
Exercise Therapy
Exercise therapy can decrease the risk of developing Alzheimer's disease [57] . An additional study of older subjects found that exercise reduces the risk of developing vascular dementia and Alzheimer's disease [58] .
Miscellaneous therapies
A new study of acupuncture combined with music therapy found that this combination Chapter-1 Page 21 approach improved a variety of measures in AD patients [59] . The commonly-used sleepinducing agent melatonin has also shown some positive effects in the AD. A new study has found that melatonin reduces the negative effects of amyloid beta proteins [60] .A new study has found that the progression of AD symptoms can be slowed down by social networking [61] .
The major spotlight of new drug development has been intended towards to find out AChE inhibitors. There is still a need to develop further proficient drugs for Alzheimer's disease. Consequently, a need for progress and utilization of alternative anticholinesterase compounds with fewer side effects leads to an investigation on plants a possible source of treatment. Plants have been used since ancient times in the treatment of several diseases including cognitive disorders, such as Alzheimer's disease. We hope that all these research in finding new drug molecules for Alzheimer's disease may still continue to focus on medicinal plants and herbal originated drugs may lead to the discovery of novel medicines. A lot of other new approaches to treatment are also under investigation worldwide. We don't yet know which of these strategies may work, but scientists say that, with the essential support, the outlook is excellent for major breakthroughs in the near future.
